Clarity Pharmaceuticals Ltd (ASX:CU6)
Australia
· Delayed Price · Currency is AUD 2.220
-0.050 (-2.20%)
Mar 28, 2025, 4:10 PM AEST
Clarity Pharmaceuticals Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | 2019 - 2018 |
| Other Revenue | 10.78 | 11.51 | 9.8 | 6.46 | 3.2 | 2.79 | Upgrade
|
| Revenue | 10.78 | 11.51 | 9.8 | 6.46 | 3.2 | 2.79 | Upgrade
|
| Revenue Growth (YoY) | 13.61% | 17.41% | 51.74% | 102.07% | 14.62% | 5.50% | Upgrade
|
| Gross Profit | 10.78 | 11.51 | 9.8 | 6.46 | 3.2 | 2.79 | Upgrade
|
| Selling, General & Admin | 12.53 | 10.52 | 4.71 | 4.61 | 3.83 | 2.82 | Upgrade
|
| Research & Development | 54.64 | 45.78 | 31.46 | 18.9 | 9.68 | 7.03 | Upgrade
|
| Operating Expenses | 67.17 | 56.31 | 36.16 | 23.51 | 13.51 | 9.85 | Upgrade
|
| Operating Income | -56.39 | -44.8 | -26.36 | -17.05 | -10.31 | -7.06 | Upgrade
|
| Interest Expense | - | - | - | - | - | -0.01 | Upgrade
|
| Interest & Investment Income | 4.55 | 2.77 | 1.86 | 0.1 | 0.04 | 0.06 | Upgrade
|
| EBT Excluding Unusual Items | -48.47 | -42.03 | -24.5 | -16.95 | -10.27 | -7 | Upgrade
|
| Other Unusual Items | - | - | - | -6.78 | 0.05 | 0.05 | Upgrade
|
| Pretax Income | -48.47 | -42.03 | -24.5 | -23.74 | -10.22 | -6.95 | Upgrade
|
| Income Tax Expense | 0.24 | 0.3 | 0.1 | 0.02 | - | - | Upgrade
|
| Net Income | -48.7 | -42.32 | -24.6 | -23.75 | -10.22 | -6.95 | Upgrade
|
| Net Income to Common | -48.7 | -42.32 | -24.6 | -23.75 | -10.22 | -6.95 | Upgrade
|
| Shares Outstanding (Basic) | 301 | 273 | 260 | 248 | 176 | 146 | Upgrade
|
| Shares Outstanding (Diluted) | 301 | 273 | 260 | 248 | 176 | 146 | Upgrade
|
| Shares Change (YoY) | 15.21% | 5.22% | 4.81% | 40.37% | 20.54% | 2.86% | Upgrade
|
| EPS (Basic) | -0.16 | -0.15 | -0.09 | -0.10 | -0.06 | -0.05 | Upgrade
|
| EPS (Diluted) | -0.16 | -0.15 | -0.10 | -0.10 | -0.06 | -0.05 | Upgrade
|
| Free Cash Flow | -47.01 | -43.74 | -27.55 | -13.53 | -7.74 | -6.84 | Upgrade
|
| Free Cash Flow Per Share | -0.16 | -0.16 | -0.11 | -0.06 | -0.04 | -0.05 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | Upgrade
|
| Operating Margin | -523.30% | -389.35% | -269.00% | -263.94% | -322.65% | -253.06% | Upgrade
|
| Profit Margin | -451.93% | -367.82% | -251.03% | -367.78% | -319.77% | -249.35% | Upgrade
|
| Free Cash Flow Margin | -436.21% | -380.14% | -281.07% | -209.43% | -242.06% | -245.44% | Upgrade
|
| EBITDA | -56.21 | -44.65 | -26.26 | -17 | -10.3 | -7.04 | Upgrade
|
| EBITDA Margin | - | - | -267.97% | -263.22% | - | -252.45% | Upgrade
|
| D&A For EBITDA | 0.19 | 0.15 | 0.1 | 0.05 | 0.02 | 0.02 | Upgrade
|
| EBIT | -56.39 | -44.8 | -26.36 | -17.05 | -10.31 | -7.06 | Upgrade
|
| EBIT Margin | - | - | -269.00% | -263.94% | - | -253.06% | Upgrade
|
| Revenue as Reported | 18.7 | 14.28 | 11.66 | 6.55 | 3.29 | 2.9 | Upgrade
|
Updated Feb 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.